Neurogene Inc. Annual Report - A Summary for Investors

I’ve put together this guide to help you understand how Neurogene performed this year. Instead of digging through dense legal filings, we’ll break down what’s happening with the company so you can decide if it fits your investment goals.

1. What does this company do?

Neurogene is a biotech company developing gene therapies for rare, neurological diseases. They are currently in the research phase, meaning they have no products for sale and earn no revenue. Their main project is NGN-401, a gene therapy for Rett syndrome. They use a proprietary platform called EXACT, which controls gene expression levels to prevent the toxicity often seen in gene therapies.

2. Financial performance

Neurogene is currently spending heavily to fund its research. For the year ending December 31, 2024, the company lost $128.5 million, up from $72.3 million in 2023. This loss grew because the company spent $107.2 million on research and development for NGN-401. Administrative costs also rose to $21.3 million due to higher staffing and public company expenses. Investors should watch their "cash burn," which currently averages $9–$10 million per month.

3. Major wins and challenges

The company’s biggest win in 2024 was advancing its clinical trial for NGN-401. They successfully dosed patients and reported early data showing the therapy was well-tolerated. However, the company relies almost entirely on this single project. Their partnership with the University of Edinburgh remains important for developing treatments for CLN5 Batten disease. Because they lack a diverse pipeline, any setback with NGN-401 would significantly hurt the company’s value.

4. Financial health

As of December 31, 2024, Neurogene had $208.4 million in cash and investments. They expect this to fund operations into the second half of 2026. To keep this runway open, the company sells more shares to the public. This process, known as an "at-the-market" offering, raises cash but results in more shares issued, which reduces your ownership percentage in the company.

5. Key risks

The biggest risk is the "all-or-nothing" nature of biotech.

• Clinical Trial Failure: NGN-401 is the company's main value driver. If future data is poor or the FDA demands more trials, the stock price could drop significantly.
• Regulatory Hurdles: The FDA’s approval process is strict. Even with good data, the FDA might ask for more safety information, delaying commercialization for years and costing millions.
• Funding and Dilution: Since the company isn't profitable, it depends on raising money from investors. If market conditions worsen, they may struggle to raise funds, potentially forcing them to pause trials or issue more shares, which lowers the value of your current holdings.

6. Competitive positioning

Neurogene works in a crowded field. They compete against established drug companies and other biotechs, such as Taysha Gene Therapies and PTC Therapeutics, which are also targeting Rett syndrome. Neurogene’s edge is its EXACT technology. They must prove this technology is safer than the methods used by their competitors.

---

Final Thought for Investors: Neurogene is a classic "high-risk, high-reward" biotech play. Because they have no revenue and are entirely focused on one lead candidate, your investment is essentially a bet on the success of NGN-401. If you are comfortable with the volatility that comes with clinical trials and the potential for share dilution, the company’s current cash runway provides a window of time to see how their technology performs. If you prefer companies with established products or more diverse pipelines, this may be one to watch from the sidelines for now.